Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Ready to Unveil First Array-Based Genotyping Tool Early '99

Premium

SANTA CLARA, Calif.--In its latest quarterly earnings report, Affymetrix noted significant progress in each of its three business areas: gene expression profiling, polymorphism analysis, and disease management. The company also unveiled a new bioinformatics product, the GeneChip Expression Data Mining Tool, during the quarter ended September 30.

In addition, Affymetrix said it continued beta-testing its first genotyping product, a GeneChip probe array containing over 2,000 common polymorphisms that was developed in collaboration with the Whitehead Institute.

The product, scheduled for launch in the first quarter of 1999, will be the first commercially available array-based genotyping tool, Affymetrix claimed.

The company reported that sales for the quarter increased 521 percent, to $6.5 million, and revenue grew 200 percent, to $15 million, compared to the same period last year.

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.